Overview

  • Product nameUBP141
  • Description
    GluN2D (formerly NR2D) antagonist, with some subunit selectivity
  • Biological descriptionGluN2D (formerly NR2D) antagonist, displaying modest GluN2 (NR2) subunit selectivity. Shows 7-fold selectivity for GluN2D (NR2D)-containing NMDA receptors vs. GluN2B (NR2B) and 5-fold selectivity over GluN2A (NR2A ) but does not discriminate between GluN2C (NR2C) and GluN2D (NR2D). Ki values are 22 (NR1/2A), 17.2 (NR1/2B), 5.24 (NR1/2C) and 2.36 μM (NR1/2D).
  • Purity> 98%

Properties

    References for UBP141 (ab120193)

    This product has been referenced in:
    • Costa BM  et al. N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse. J Pharmacol Exp Ther 331:618-26 (2009). Read more (PubMed: 19684252) »
    • Brothwell SL  et al. NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones. J Physiol 586:739-50 (2008). Read more (PubMed: 18033813) »
    • Morley RM  et al. Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem 48:2627-37 (2005). Read more (PubMed: 15801853) »

    See all 8 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120193.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"